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Abstract: HTRF (Homogeneous Time Resolved Fluorescence) is the most frequently used generic assay technology to 
measure analytes in a homogenous format, which is the ideal platform used for drug target studies in high-throughput 
screening (HTS). This technology combines fluorescence resonance energy transfer technology (FRET) with time-
resolved measurement (TR). In TR-FRET assays, a signal is generated through fluorescent resonance energy transfer be-
tween a donor and an acceptor molecule when in close proximity to each other. Buffer and media interference is dramati-
cally reduced by dual-wavelength detection, and the final signal is proportional to the extent of product formation. The 
HTRF assay is usually sensitive and robust that can be miniaturized into the 384 and 1536-well plate formats. This assay 
technology has been applied to many antibody-based assays including GPCR signaling (cAMP and IP-One), kinases, cy-
tokines and biomarkers, bioprocess (antibody and protein production), as well as the assays for protein-protein, protein-
peptide, and protein-DNA/RNA interactions. 
Since its introduction to the drug-screening world over ten years ago, researchers have used HTRF to expedite the study 
of GPCRs, kinases, new biomarkers, protein-protein interactions, and other targets of interest. HTRF has also been 
utilized as an alternative method for bioprocess monitoring. The first-generation HTRF technology, which uses Europium 
cryptate as a fluorescence donor to monitor reactions between biomolecules, was extended in 2008 through the 
introduction of a second-generation donor, Terbium cryptate (Tb), enhancing screening performance. Terbium cryptate 
possesses different photophysical properties compared to Europium, including increased quantum yield and a higher 
molar extinction coefficient. In addition to being compatible with the same acceptor fluorophors used with Europium, it 
can serve as a donor fluorophore to green-emitting fluors because it has multiple emission peaks including one at 490 nm. 
Moreover, all Terbium HTRF assays can be read on the same HTRF-compatible instruments as Europium HTRF assays.  
Overall, HTRF is a highly sensitive, robust technology for the detection of molecular interactions in vitro and is widely 
used for primary and secondary screening phases of drug development. This review addresses the general principles of 
HTRF and its current applications in drug discovery. 
Keywords: HTRF, TR-FRET, GPCR, Kinase, Biomarker, Bioprocess. 
INTRODUCTION 
  Utilizing rare-earth lanthanides with long emission half-
lives as donor fluorophores, HTRF technology combines 
standard FRET with the time resolved measurement (TR) of 
fluorescence [1,2]. This powerful combination provides sig-
nificant benefits to drug discovery researchers in high 
throughput screening (HTS), including assay flexibility, reli-
ability, increased assay sensitivity, higher throughput, and 
fewer false positive/false negative results. These features, 
allied with automated liquid handling and robust detection 
instrumentation, allow for a broad range of applications in 
HTS. 
  The principle behind FRET is based on the transfer of 
energy between two fluorophores, a donor (long-lived fluo-
rescence) and an acceptor (short-lived fluorescence), when  
in close proximity [3, 4]. Molecular interactions between   
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biomolecules can be assessed by coupling each partner with 
a fluorescent label and detecting the level of energy transfer 
(Fig. 1). In the past, organic fluorescent compounds such as 
fluorescein and rhodamine have been widely used in the 
regular fluorescence assay. However, these bioassays have 
great disadvantages in that fluorescent detection because it is 
dramatically inhibited by noise in the back ground derived 
from scattered excitation light and significantly interfered by 
fluorescence from coexisting material in the sample (fluores-
cent compounds and dust/line), making it difficult to obtain a 
highly sensitive measurement. Through time-resolved meas-
urement of fluorescence, HTRF allows the elimination of 
short-lived background fluorescence. Introducing a time   
delay (50-150 microseconds) between the initial light excita-
tion and fluorescence measurement minimizes the contribu-
tion of all non-specific short-lived fluorescence emissions. In 
contrast, HTRF acceptor fluorophores emit long-lived fluo-
rescence when engaged in the TR-FRET process with a 
long-lived donor fluorophore, signifying energy transfer 
through proximity of the labeled biomolecules (Fig. 2). 
  Four specific fluorophores are used in HTRF forming 
different TR-FRET systems. The central element, the energy 
donor, is either Europium cryptate (Eu
3+ cryptate) (Fig. 3a) HTRF: A Technology Tailored for Drug Discovery  Current Chemical Genomics, 2009, Volume 3    23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The general principle of fluorescence resonance energy transfer technology (FRET). When the donor and acceptor apart, there is no 
FRET signal. Once they are brought in proximity, the FRET signals are generated (for example, the emission spectrum at 665 nm). 
[5] or Lumi4-Tb (Tb
2+ cryptate) (unpublished structure) (Fig. 
3b). These rare earth complexes, based on the work from 
Nobel Prize laureate, Professor Jean-Marie Lehn, and from 
Professor Raymond respectively, have a macrocycle within 
which a Eu
3+ ion or Tb
2+ is tightly embedded. These ions are 
not fluorescent on their own; they need a light-collection 
device (i.e. the cage) to be excited. Similar to functions of 
the chelate in other luminescent lanthanide technologies, this 
cage acts as an antenna and allows both energy collection 
and transfer to the ions, which ultimately releases this energy 
with a specific fluorescent pattern. In particular, these cryp-
tates are not subject to the photo-bleaching that affects a 
number of more conventional fluorophores, and the ions are 
almost inseparable from their macrocycles [5]. However, due 
to the unique caged structure, the kinetics stability of the 
cryptate is extremely higher than the one of those lanthanide 
chelates [3]. Rare earth chelates would be dissociated and 
unstable in acidic media or in the presence of divalent ions 
like Mn
2+, while rare earth cryptates are extraordinarily   
stable under wide range of chemical conditions, like reverse 
phase chromatography in the presence of trifluoroacetic acid, 
and are not affected by the presence of divalent ions in the 
media [4]. It therefore allows for enhanced assay perform-
ance in terms of sensitivity, assay window, and robustness, 
without compromising the features and benefits that HTRF 
brings to assays: a ‘mix and measure’ non-radioactive   
format, miniaturizable to uHTS formats, showing excellent 
robustness and a low compound interference rate (Fig. 3). 
Lumi4-Tb’s structure, a lanthanide tightly embedded in a 
surrounding macrocycle, remains very much in line with that 
of previous HTRF cryptates and shows superior stability 
compared to other Terbium complexes. Terbium is excep-
tionally bright – 10 to 20 times brighter than Europium that 
significantly increases the detection sensitivity in assays 
such as the exploration of cell surface receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The energy pulse from the excitation source (flash lamp, 
laser) is followed by a time delay, allowing interfering short-lived 
fluorescence (compounds, proteins, medium etc.) to decay. The red 
line: FRET signal intensity generated at 665 nm; black line, emis-
sion of donor cryptate at 620 nm; orange line, fluorescent signal 
generated from acceptor fluorophores.  
 
  The first acceptor developed for HTRF was XL665, a 
phycobiliprotein pigment purified from red algae [6]. XL665 
is a large heterohexameric edifice of 105 kDa, cross-linked 
after isolation for better stability and preservation of its pho-
tophysical properties in HTRF assays [6]. Unlike fluo-
rescein, it is fully compatible with Eu cryptates. It is red-
shifted and its emission is more likely to be away from 24    Current Chemical Genomics, 2009, Volume 3  Degorce et al. 
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Fig. (3). Features of donor cryptate. a. Structure of cryptate trisbipyridine (TBP). Lambda max absorption: 305nm, molar extinction coeffi-
cient at 305nm: 30000 M-1 cm-1, molar extinction coefficient 337nm: 4500 M-1 cm-1. b. Detection wavelengths for Europium and Terbium 
cryptate. Both Europium and Terbium have emission spectra at 620 nm so that these signals can be used as reference for data analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Ratiometric reduction of the signal output data.  
The specific signal at 665 nm may be affected by light transmission. The ratio (i.e. 665nm/620 nm) will normalize the signal measured and 
generate a variable that is independent of the optical properties of the medium in which the interaction is studied. In the case shown above, 
the 665 nm fluorescence decreases proportionally to the transmission, whereas the ratio corrects this interference and is equivalent in both 
situations.  
possible medium and compound interference. The second-
generation acceptor, d2, possesses a series of photophysical 
properties very similar to those of XL665 but is character-
ized by organic structures 100 times smaller than XL665. As 
a much smaller entity, d2 limits the steric hindrance prob-
lems sometimes suspected in XL665 based TR-FRET   
systems. These near-infrared acceptors are also particularly 
suited for homogeneous assays since their emission is less 
likely to be disturbed by intrinsic medium or compound 
autofluorescence arise in the typical compound screen proc-
ess. The properties of these red acceptors also make them 
suitable for coupling with Terbium cryptate. Moreover, due 
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to additional peaks in its emission spectrum, Terbium cryp-
tate can be coupled with green acceptors such as fluorescein, 
emitting in the 520 nm range that may for instance allow 
designing multiplex assays with two readouts. 
  HTRF emissions are measured at two different wave-
lengths, 620nm (donor) and 665nm (acceptor). This feature 
is extremely advantageous, particularly for reducing well-to-
well variations that may arise in homogeneous assay   
formats. Because wells contain a range of compounds and/or 
medium additives, each well will have different photophysi-
cal properties and cause varying degrees of signal interfer-
ence and therefore altered signal intensities. This well-to-
well signal variation is not due to true differences in light 
transition, but it can lead to misleading results if only a   
single emission wavelength is measured. A unique ratio-
metric measurement of two emission wavelengths (patent 
US 5,527,684 and foreign equivalents) corrects for well-to-
well variability and signal quenching from assay components 
and medium variability. Emissions at 620nm (donor fluor) 
are used as an internal reference while emissions at 665nm 
(acceptor fluor) are used as an indicator of the biological 
reaction being assessed. Because both the 620nm and 665nm 
emissions are decreased by sample interferences, the ratio 
remains unchanged (Fig. 4). In addition, the ratiometric 
readout can minimize the system errors caused by liquid 
handling instruments and detectors. 
HTRF ASSAY APPLICATIONS 
GPCR Investigation and Screening 
  GPCRs have offered a broad playfield to HTRF devel-
opment and the assays that have been described may be 
segmented into two categories: functional assays and 
mechanistic assays. Functional assays have been based on 
the quantification of secondary messengers, whose concen-
tration correlates tightly to events occurring at the cell   
surface receptor level, such as ligand binding. They are part 
of a signaling cascade that may be blocked by specific   
inhibitors to enable their accumulation in the cell.  
  Cyclic AMP has long been used as a secondary 
messenger, as its production results from the up or down 
regulation of adenylate cyclase upon Gs and Gi-coupled 
receptor activity. The HTRF assay was developed based on 
the detection on cAMP (Fig. 5). On the other hand,   
Gq-coupled receptors activate the phospholipase C pathway 
(PLC), which acts upstream to the inositol phosphate 
cascade. Thus far, the main readout consisted of the 
detection of calcium release triggered by IP3, one on the 
cascade’s metabolites. The assessment of IP3 as a potential 
secondary messenger has been hampered by its extreme 
instability, as no inhibitor of the cascade is known to block 
its degradation. The measurement of total inositol phosphate 
metabolites by radioactive uptake translates receptor activity 
well, however, these methods are far from being   
HTS-friendly. Recently, Trinquet et al. demonstrated that 
inositol-1-phosphate, a sub-metabolite of the same pathway, 
could be accumulated in the cell in the presence of Lithium 
Chloride, an agent inhibiting downstream phosphatases [7]. 
Similarly to cAMP assay development, the generation of 
specific high affinity monoclonal antibodies have enabled 
the optimization of the HTRF IP-One assay [7, 8].  
  The application of HTRF to functional detection of 
GPCRs has been illustrated for many receptors including 
5HT4 and 5HT6 [9, 10], BLT1 and cysLT1 leukotriene   
receptors [11], canabinoid receptors [12, 13], H1, 2 and 3 
receptors [14, 15], PTH receptor [16], PACAP and PAR1 
[17, 18] and a number of orphan receptors such as GPR22, 
30 or 109 [19-21]. The assay system allows several advan-
tages over existing methodologies. First, the robustness of 
the chemistry makes it suitable for most cell-based experi-
mental procedures, allowing the direct measurement of the 
cell lysate in the presence of cell culture medium [8, 22, 23]. 
Second, these assays are capable of being highly miniatur-
ized, making them particularly adaptable to HTS [22, 24]. 
Third, the cellular accumulation of secondary messengers 
has proven advantages over more transient readouts such as 
calcium flux for instance. As recently demonstrated, the 
identification of slow-acting compounds on Gq-coupled   
targets via IP1 assessment (unpublished data) confirm more 
general previous findings suggesting the potential for the   
IP-One assay to be used as an orthogonal screening method 
[25]. Finally, Jean et al. have recently shown that the sensi-
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). cAMP assay principle. In this competitive assay, an anti-cAMP antibody is labeled with a cryptate donor and cAMP is labeled with 
acceptor d2. Once both of them are place together, the binding of antibody to cAMP brings donor and acceptor into proximity range. Upon 
the excitation of donor at 337 nm, the energy is transferred from donor to acceptor. Donor and acceptor generate emission at 620 nm and 665 
nm, respectively. In the cAMP assay, the level of free cAMP generated by the signal cascade can be measured by competing with the cAMP 
d2 for antibody binding. IP-One assay from HTRF has the similar principle. 26    Current Chemical Genomics, 2009, Volume 3  Degorce et al. 
tivity of these methodologies could enable the detection of 
these secondary messengers in rat native cerebral tissues [9]. 
In a recent communication, Trinquet et al. have also demon-
strated how the detection of two secondary messenger could 
be multiplexed (unpublished data) thereby offering a way to 
detect simultaneously different signal mediations from the 
same GPCR. Taking advantage of the fact that the new 
Lumi4-Tb donor can be associated with different acceptors, 
and using V2 and M1 receptors, cAMP was run as a fluo-
rescein assay while IP1 detection was performed with the 
standard d2 near-infrared dye. Both assays could be run and 
detected in the same well using the same cellular material 
and confirmed receptor responses for both pathways upon 
agonist stimulation.  
  The second field of application of HTRF methods was 
developed with the emergence of new concepts around 
receptor organization at the cell surface. Upon increasing 
evidence that a large number of receptors oligomerize at the 
cell surface to mediate intracellular signaling, researchers 
have started to develop methodologies that enable the 
detection of such rearrangements. These mechanistic studies 
have first been undertaken with antibodies specific to 
receptors or to encoded tags, and several groups have been 
able to investigate, among others, the way A1-A2 receptors 
assemble and permit adenosine to modulate glutamatergic 
neurotransmission [26], how BILF1 and chemokine receptor 
oligomerization may contribute to the alteration of the 
immune response [27], or mGlu and GABA receptors 
organization at the cell surface [28, 29]. We will further 
discuss the receptor oligomerization in the section of 
Protein-Protein/Protein-Peptide/Protein-DNA Interaction 
Assays. Because the use of conjugated antibodies is 
sometimes limiting, new labeling techniques based on 
suicide enzyme technologies like SNAP-tag were applied to 
address the same receptor mechanistics. Maurel et al. [30] 
have used specific HTRF fluorophore-labeled benzyl 
guanine substrates to covalently label SNAP-encoded GABA 
receptors and investigate their organization at the cell 
surface. These recent optimizations and findings preclude a 
new field of application for HTRF applied to receptor 
investigation, particularly for ligand binding and receptor 
trafficking.  
Kinase Assays 
  HTRF technology has been applied to a number of en-
zymatic activity assays, such as kinases, proteases, ubiquiti-
nation, etc. There are two major formats for HTRF in these 
assays, a “sandwich” format to measure the signals gener-
ated from the status change of a labeled substrate, such as 
phosphorylation and cleavage by proteases; and a competition 
format to monitor the other products generated in the reac-
tions, such as ADP production in the kinase assays (Fig. 6). 
Serine/Threonine Kinase Assays 
  Protein kinases are key elements in intracellular signaling 
pathways that control many physiological processes and the 
activities of protein kinases are altered in a number of human 
diseases such as cancer and autoimmune disorders [31-33]. 
The rapidly growing interest in kinases as potential targets 
for therapeutic intervention has prompted the development 
of many kinase assay technologies. HTRF-based tools for 
HTS could apply to all kinases, with specific applications for 
Tyrosine (Tyr) and Serine/Threonine (Ser/Thr) kinases. This 
kinase screening platform offers the ability to use a single 
technology for both universal and specific kinase assays, 
saving valuable development time and cost (Fig. 7). A com-
prehensive review summarized the recent literatures and 
meeting reports on HTRF kinase assay [34].  
  HTRF KinEASE is a universal and sensitive assay allow-
ing for profiling and HTS of a large range of Ser/Thr 
      a         b  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). The comparison of “sandwich” assay and competition assay. a. “Sandwich” assay. HTRF signals are generated through the energy 
transfer from donor to acceptor that are labeled on the antibodies recognizing the target at different regions. b. Competition assay. Targets 
generated through biological events compete binding activity to the donor labeled antibody with the target labeled with acceptor so that the 
decrease of the HTRF signals are measured. HTRF: A Technology Tailored for Drug Discovery  Current Chemical Genomics, 2009, Volume 3    27 
kinases. This platform consists of three different biotinylated 
substrates and a single proprietary monoclonal anti-phospho 
antibody labeled with Eu
3+ cryptate recognizing only the 
phosphorylated substrates, and streptavidin-XL665. Each 
peptide has a common C-terminal phospho-serine epitope 
with three different N-terminal sequences allowing access to 
a large range of kinases. FRET signals are generated once 
the monoclonal antibody binds to the phosphorylated serine 
in the biotinylated peptide that in turn is bound to strep-
tavidin-XL665. It is highly likely that many more kinases 
will phosphorylate one or more of the three peptides. Using 
this universal kinase activity detection tool and other more 
specific substrates, numerous assay systems have been suc-
cessfully built to monitor protein kinase activity with puri-
fied enzymes, as well as with cellular lysates and membrane 
preparations, including COT [35], AKT [36], and Rock II 
[37]. Recently a cellular Ser/Thr-kinase platform was devel-
oped by co-expression of targeted kinases with a generic 
peptide substrates followed by quantification of phosphory-
lation on intracellular substrate by HTRF [38]. Although the 
development of this platform is still in the early stage, the 
proof-of principle assays were shown that activity of cellular 
AKT, B-RAF and CamK2 could be detected and IC50 
could be measured [38]. To date, this KinEASE screening 
platform has been validated on over 160 kinases.  
Tyrosine Kinase Assays 
  Based on the same monoclonal antibody principle as 
HTRF KinEASE, HTRF KinEASE TK was developed to 
measure tyrosine kinase activity [39]. Compared to the well-
known universal tyrosine kinase substrates, poly(GT) and 
poly (GAT), the TK substrate has shown vast flexibility in 
assay design without sacrificing assay performance and its 
single phosphorylation site makes kinetic determinations 
such as Km apparent easily investigated [40]. The applica-
tion of HTRF on tyrosine kinases have been demonstrated in 
many reports, including Lck [41], FGF receptor [42], c-kit 
[43], c-Met [44], IGF-1R [45], KDR (kinase insert domain 
receptor (a type III receptor tyrosine kinase)) [46], and Tie2 
[47]. So far, at least 59 unique tyrosine kinases have been 
validated by the HTRF KinEASE TK platform. 
  In contrast to the above sandwich format, HTRF Tran-
screener ADP is a universal and flexible assay for profiling 
and HTS of all kinases and ATPases using a competition 
format. This homogeneous, non-radioactive competition 
assay measures the generation of ADP (Adenosine 5’-
diphosphate), which is directly detected by a specific anti-
ADP antibody labeled with Eu3+ cryptate, and correlates 
tightly with the amount of phosphorylated substrate. Because 
the assay measures ADP and not the substrate itself, it is 
compatible with any substrate. The enzyme-free detection 
system also provides an alternative with less interference and 
a lower false positive rate than assays whose detection   
systems involve the use an enzyme to measure ATP deple-
tion. The HTRF Transcreener ADP assay is particularly   
suitable when measuring difficult kinases for which no anti-
phospho-specific antibody is available.  
Other Enzyme Assays 
  HTRF has been used to measure the activity of 
heparanase [48]. Heparanase functions as an enzyme 
cleaving heparan sulfate proteoglycan to release growth 
factors and plays an important role in tissue invasion by 
malignant tumor cells and inflammatory cells. In this assay, 
biotinylated heparan sulfate proteoglycan labeled with 
Europium cryptate served as the substrate for heparanase. 
Heparanase activity resulting in substrate cleavage by murine 
melanoma cell extracts was detected by measuring the HTRF 
signal after addition of streptavidin-XL665. Subsequently, a 
rapid process for screening large numbers of samples can be 
established by the HTRF Heparanase assay. 
  Ubiquitination is one of the major post-translational 
modifications that proteins regularly undergo prior to degra-
dation in the proteosome. The ubiquitin pathway is associ-
ated with many pathologies such as cancer, muscle atrophy, 
inflammation, viral infection, and metabolic and neurode-
generative disorders. Ubiquitination is carried out by the 
conjugation of ubiquitin to target proteins through the   
sequential activity of three enzymes: E1, E2 and E3. Poly-
ubiquitinated proteins are then subject to degradation by pro-
teasomes. In order to monitor p53 poly-ubiquitination, a 
HTS assay system using HTRF has been established [49]. In 
the ubiquitination reaction, Europium cryptate-labeled ubiq-
uitin is incorporated as poly-ubiquitin chains onto the   
biotinylated p53 target protein. The assay is stopped by the 
addition of streptavidin-XL665 in a buffer containing EDTA 
before being read. The HTRF Ubiquitin assay is robust 
enough to be used in synthetic compound screening and has 
almost the same level of sensitivity as that monitored by the 
scintillation proximity assay (SPA) using 
125I-labeled ubiq-
uitin. The HTRF Ubiquitin assay was recently used as a   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Kinase assay principle. The substrates used in HTRF 
kinase assays are tagged by fusion proteins, peptides, or biotin. An 
antibody to these proteins or peptides, or streptavidin (for biotin in 
this case) is labeled with acceptor. An antibody against phosphory-
lated substrate is labeled by donor cryptate. In the enzymatic reac-
tion, once substrate is phosphorylated, donor and acceptor can be 
brought into proximity by affinity interactions of antibod-
ies/substrate or streptavidin/biotin. 28    Current Chemical Genomics, 2009, Volume 3  Degorce et al. 
research tool to measure self-ubiquitination of POSH (plenty 
of SH3s) [50]. 
Protein-Protein/Protein-Peptide/Protein-DNA Interaction 
Assays  
  Protein-protein, protein-peptide, and protein/DNA inter-
actions are involved at almost every level of cell function, in 
surface protein communication (e.g. GPCR dimerization, 
surface molecule interaction, and receptor-ligand binding), in 
signal transduction machinery across various biological 
membranes (e.g. G-protein cascades, kinase/substrate inter-
actions), the regulation of gene expression (e.g. interaction 
of transcription factors with co-activators or co-repressors 
and transcription factors with DNA), the packaging of chro-
matin, etc. Several applications using HTRF in these interac-
tions have been demonstrated to date. The general principle 
of these assays is very similar. A pair of antibodies against 
the target proteins or the tags that they are fused to is labeled 
with the HTRF donor and acceptor fluorophore, respectively. 
The interaction of target proteins brings the antibodies into 
close proximity, generating the FRET signal (Fig. 8).  
Cell Surface Protein Interaction 
  It is well established that membrane receptors may   
dimerize to regulate the activity of each member of the dimer 
or to work cooperatively to bind ligand on one receptor 
while mediating intracellular signaling through the other. In 
2004, the Pin lab pioneered the work demonstrating the   
application of HTRF in studying dimerization of glutamate 
and  -aminobutyric acid (GABA) receptors [51]. In this 
study, anti-tag (Flag, HA, and 6-His) antibodies labeled with 
donor Eu cryptate and acceptor AlexaFluor 647 or XL665 
were used to generate fluorescent signals. The mechanism of 
this dimerization was further pursued by HTRF technology 
[29]. Recently, the application of HTRF on GPCR   
oligomerization and receptor-ligand binding was further   
expanded with SNAP-Tag technology as mentioned above 
[30] (and data not shown). The Pin lab later conducted a   
series of studies using HTRF to demonstrate the dimerization 
of other GPCRs, such as metabotropic glutamate-like recep-
tors (mGluR) [28, 52], vasopressin and oxytocin receptors 
[53]. Ciruela et al. developed an HTRF assay to measure the 
heterodimerization of adenosine A1 receptors (A1Rs) and 
A2A receptors (A2ARs), revealing a more precise modulation 
of glutamatergic neurotransmission by adenosine [26]. The 
human hemagglutinin (HA)-A2AR and Flag-A1R constructs 
were generated and transiently transfected into HEK cells. 
The level of heterodimerization of the receptors was   
reflected through the FRET generated when Eu-labeled anti-
Flag antibody and XL665-labeled anti-HA antibody were 
incubated with these transfected cells [26].  
  In addition to utilizing HTRF to study GPCR dimeriza-
tion such as the dimerization of orphan GPR50 receptor with 
MT1 and MT2 melatonin receptors [54], many groups have 
used HTRF technology to study higher order oligomer for-
mation of the Dopamine D2 receptor [55], oligomerization 
of human histamine H4 receptor [56], and to determine the 
function of C-terminal ends of mGluR1 in subunit associa-
tion [57]. It has also been used to study chemokine receptors 
(reviewed by Wang and Norcross [58]) and the interaction of 
surface molecules, such as Trail receptor 4 and OX40 [59], 
CD80 and CD28 [60], and adhesive molecule Chemokine 
(C-X3-C motif) ligand 1 (CX3CL1) aggregation [61]. 
Moreover, the protein – peptide interaction was demon-
strated with HTRF technology in cell surface calreticulin 
(CRT) and Shared Epitope (SE) from HLA-DR chain [62]. 
Viral Protein Interactions with Human Proteins 
  Viruses interact with protein machinery in intact cells to 
propagate in order to maintain functionality in infectious 
disease and oncology. For example, reverse transcription 
complex (RTC) is formed by viral genomic RNA associated 
with viral proteins (including RT) and, presumably, as yet 
uncharacterized cellular proteins from human immunodefi-
ciency virus type 1 (HIV-1) infected cells. Lemay et al.  
reported an HTRF assay to confirm the yeast two-hybrid 
results that nucleocytoplasmic shuttling protein – the RNA-
binding protein HuR is the cellular protein in RTC to interact 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Principle of protein-protein interaction. Antibodies against the desired proteins (CD28 and CD 86 as examples) for interaction or the 
fused tags on these proteins are labeled with donor and acceptor, respectively. The FRET signals are generated once these proteins interact 
with each other to bring the labeled antibodies in into proximity. HTRF: A Technology Tailored for Drug Discovery  Current Chemical Genomics, 2009, Volume 3    29 
with viral RT [63]. In 2002, Leblanc et al. showed that 
SV40-LTAg interacts with p53 by using the antibodies   
directly against them labeled by Eu cryptate and XL665, 
respectively [64]. Another HTRF assay showed that HIV 
integrase (IN) interacts with SNF5, a subunit of the 
SWI/SNF chromatin remodeling complex [65]. Interestingly, 
Epstein-Barr virus (EBV) BILF1 gene, which is a GPCR, 
has been shown with HTRF assays to form heterodimers 
with various chemokine receptors, altering the respon-
siveness of B lymphocytes to chemokines that is essential for 
EBV dissemination and/or involved in EBV-induced patho-
genesis [27].  
Protein/DNA Binding Assay 
  HTRF technology has also been useful in monitoring the 
interaction of protein/DNA, such as transcription factors 
binding with their regulatory elements on DNA or RNA. The 
MutS protein is part of the dam-directed MutHLS mismatch 
repair pathway in Escherichia coli. By using directly labeled 
MutS with europium cryptate, Lopez-Crapez et al. have   
developed an HTRF assay to measure interactions between 
MutS and mismatched DNA or DNA containing the most 
common lesion of the anticancer drug cisplatin [66].  
Biomarker Detection 
  Monitoring the production of biomarkers is a useful tool 
for examining aberrant cell signaling processes often associ-
ated with diseases in therapeutic areas such as inflammation, 
metabolism and neuroscience. Understanding the relation-
ship between the production of these downstream signaling 
products and the upstream effectors of signaling cascades is 
not only important for mapping the signaling pathways, but 
is also useful in identifying specific agents of therapeutic 
value for a particular disease state.  
  In this light, HTRF has proven a viable technology for 
constructing assays that can be used to examine the in-vivo 
production of biomarkers measured in either whole cells or 
cell supernatants, as well as serve as a platform for monitor-
ing the in-vitro production of biomarkers via the enzymatic 
modifications of proteins. Such assays typically involve a 
sandwich or competition format. 
  Cell based assays employing HTRF to the direct meas-
urement of protein biomarkers have allowed researchers to 
gain a better understanding of the biology behind signaling 
processes. Elucidation of signaling pathways and their regu-
latory mechanisms allows researchers to better identify   
targets for therapeutic intervention. By applying HTRF   
assays to directly measure IL-6 and IL-8 production by cells  
resulting from TNF stimulation, as well as stimulation by   
other immune stimuli, researchers were able to establish the  
essential functional role of a regulatory protein, called   
TMEM9B, in the production of these cytokines [67].  
  HTRF biomarker detection assays can also be used to 
monitor cellular responses to novel pharmacological sub-
stances and screen for potential therapeutic agents in many 
disease pathways. Two such biomarker detection assays   
include the measurement of insulin and cortisone. Insulin has 
been well established as a key regulator in glucose homeo-
stasis. Deficiency of insulin leads to insulin-dependent (type 
1) diabetes, whereas abnormal insulin secretion and resis-
tance to insulin action is common in non-insulin-dependent 
(type 2) diabetes. An HTRF assay for the measurement of 
insulin has been developed that can be used to quantify both 
secreted and intracellular insulin. Such an assay has clear 
utility for the investigation of novel anti-diabetic agents. 
Researchers used HTRF to measure the insulin response of 
cells treated with various amounts glucose as well as an 
agent of potential therapeutic value to ascertain its effective-
ness at promoting insulin production [68]. Other recently 
published applications of HTRF in cell-based assays have 
highlighted its utility for monitoring cortisol production in 
cell cultures. This application was used to characterize and 
identify inhibitors of the enzyme 11beta-Hydroxysteroid 
Dehydrogenase Type 1 (11-HSD1). Inhibition of this target 
is believed to have therapeutic value in the treatment of type 
2 diabetes as well as in metabolic syndrome. Cell-based   
assays directly measuring cortisol production have been used 
to monitor the activity of 11-HSD1 in screening for inhibi-
tors of the cellular enzyme [69,70].  
  Utility of these same HTRF biomarker assays has   
extended into the development of biochemical-based enzyme 
screens as well, including targets such as prostaglandin E2 
synthase and 11-hydroxysteroid dehydrogenase 1 (11-
HSD1). Recently, the development of an assay to measure 
the activity of microsomal prostaglandin E2 synthase-1 
(mPGES-1) was described in the literature. The authors used 
an HTRF assay to directly detect prostaglandin E2 formed 
by the enzyme. This assay proved useful in assessing the 
activity of the enzyme as well as determining the potency of 
inhibitors [71]. Previous methods used for measuring the 
activity of this enzyme have proven labor intensive. Also, an 
article was recently published that described a biochemical 
assay for measuring human 11-HSD1 activity. In this   
instance, the authors have applied the HTRF detection of   
cortisol production to screening for inhibitors of the enzyme  
contained in human liver microsome fractions [72]. In   
another publication, researchers describe the use of the same  
cortisol measurement kit to monitor 11-HSD1 activity in   
order to elucidate the relationship of the cofactor   
NADPH/NAD+ ratio to the reductase activity of the enzyme  
[73]. Understanding the enzyme and cofactor relationship is  
important for constructing screens to correctly measure for  
modulators of the different activities. 
  The assays described above highlight just some of the 
quantitative biomarker assays that have been developed   
using HTRF. Other examples of HTRF biomarker assays 
developed include: cGMP, histamine, IL-2, IL-17, estradiol, 
Leukotriene B4 (LTB4) and Amyloid  1-40. 
  In addition to drug discovery applications, investigative 
applications of the quantification of biomarkers with HTRF 
have allowed researchers to examine the clinicopathology of 
diseases such as vascular dementia. By measuring the levels 
of Amyloid- in brain samples from diseased individuals vs. 
age-matched controls, researchers were able to identify a link 
between the presence of these proteins and vascular demen-
tia [74].  
Bioprocess 
  In addition to its broad applications in investigation of 
new drug targets, HTRF shows other niches, such as moni-
toring the manufacturing of biotherapeutics to insure safety 
and quality. Antibodies are of interest in their potential for 30    Current Chemical Genomics, 2009, Volume 3  Degorce et al. 
therapeutic use and a significant portion of new drugs stem 
from the biopharmaceutical industry. The compatibility of 
HTRF technology with cell culture media and other biologi-
cal materials makes it applicable in the quantification of hu-
man antibodies and Fc fragments/human Fc-tagged chime-
ras. HTRF bioprocess assays are a highly sensitive and cost-
effective alternative to automated systems and other methods 
used to screen for positive clones and high-producing clones 
during the antibody engineering and selection process [75]. 
The Human MAb assay is a competitive immunoassay for 
the measurement of all isotypes of human IgGs and Fc-
tagged proteins. The assay utilizes an antibody specific to 
human Fc IgGs conjugated to europium cryptate and human 
IgG conjugated to XL665. The assay is run with a minimal 
number of additions: a sample of the antibody being assayed 
is titred into 96-, 384-, or 1536-well assay plates followed by 
the addition of detection reagents and then allowed to incu-
bate at room temperature for 2 hours before being read.  
  Additionally, HTRF may be used to quantify and/or 
detect the presence of tagged protein during protein 
production and through each step of the purification process. 
The assay for GST- or 6HIS-tagged proteins is similar to that 
of the Human MAb assay. It is a competitive immunoassay 
in which an anti-tag antibody is coupled to europium 
cryptate and GST or 6HIS-peptide is coupled to XL665. The 
tagged fusion protein competes with the XL665 conjugate 
for binding to the anti-tag-cryptate conjugate and the signal 
is inversely proportional to the concentration of tagged 
fusion protein. 
  Most bioprocess ELISA assays can be easily converted to 
a no-wash, one-step HTRF assay. HTRF can be applied in 
several other ways to increase productivity in a bioprocess 
research facility, for instance, through monitoring cellular 
impurities which play a role in immunotoxicity [76]. 
CONCLUSION 
  HTRF is widely used in drug discovery and HTS. Even 
though this technology is extremely sensitive, versatile, and 
well adapted to automation for HTS, intrinsic limitations 
also exist, for example, quenching generated by external 
interactions with the intramolecular excitation process (elec-
tron transfer, FRET, and bleaching) and fluorescence of   
library compounds or biological proteins. It is our experience 
that the results obtained by using fluorescent techniques that 
do not use ratiometric measurement and/or time resolution 
should be carried out and validated with great care in order 
to avoid false positive or negative results. 
  Recently alternative methods were developed to measure 
the second messenger accumulation. However, classical 
HTRF applications on other cell signaling process such as 
phosphorylation, proteolysis, ubiquitination, and glycosyla-
tion, remain irreplaceable. The different photophysical prop-
erties of Terbium cryptate and its compatibility with not only 
red acceptors but also green acceptors open new doors to 
multiplexing with HTRF. Moreover, ligand-binding assays 
that are selective for cell-surface receptors run more effi-
ciently with Terbium than Europium cryptates (unpublished 
data). Most recently, the introduction of Terbium cryptate 
and SNAP-Tag into the HTRF portfolio broadens HTRF 
applications, for instance, by allowing to study receptor   
dimerization, receptor mechanistics (internalization and   
dimerization), and by providing a non-radioactive alternative 
to ligand binding assays on whole, live cells [30]. 
  Additional information for HTRF assays and other 
related reagents can be found on the web at www.HTRF.com. 
Lumi4® is a trademark of Lumiphore Inc. 
HTRF KinEASE
TM is developed with Millipore. 
HTRF Transcreener
TM ADP assay is licensed from 
BellBrook Lab. 
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